Skip to main content
Log in

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide (111In-DOTA-TOC) and 111In-DOTA-lanreotide (111In-DOTA-LAN) has been used for staging of neuroendocrine tumours (NETs). However, the comparative diagnostic value of these radioligands on a lesion basis has not yet been established. The aim of this study was to compare the diagnostic capacity of 111In-DOTA-TOC and 111In-DOTA-LAN scintigraphy in patients with NETs, evaluating whether significant differences exist in lesion imaging with these radioligands. Furthermore, dosimetric data were compared.

Methods

Forty-five patients with NETs were investigated with 111In-DOTA-TOC and 111In-DOTA-LAN scintigraphy. Scintigraphic results were compared with those of conventional imaging and/or surgery in each patient, and also 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in 20 patients.

Results

111In-DOTA-TOC and 111In-DOTA-LAN scintigraphy were true positive in 42/45 (93%) and 39/45 (87%) patients, and imaged 74/91 (81%) and 73/91 (80%) tumour lesions, respectively. 111In-DOTA-TOC and 111In-DOTA-LAN detected liver metastases in 21 and 14 patients, mediastinal metastases in seven and 11 patients, and bone metastases in two and seven patients, respectively. These radioligands revealed lesions not seen by conventional imaging in seven and eight patients, respectively, or by 18F-FDG-PET in eight and seven patients, respectively. The estimated tumour absorbed doses for 90Y-DOTA-TOC were higher than those for 90Y-DOTA-LAN in 14 patients, whereas the opposite was true in 12 patients.

Conclusion

Both 111In-DOTA-TOC and 111In-DOTA-LAN are suitable for imaging tumour lesions in patients with NETs and can detect lesions that may not be seen by conventional imaging and 18F-FDG-PET. Compared with 111In-DOTA-LAN, 111In-DOTA-TOC has a superior diagnostic capacity for liver metastases, but a lower diagnostic capacity for metastatic lesions in mediastinum and bone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999;26:877–86

    Article  PubMed  CAS  Google Scholar 

  2. Kölby L, Wängberg B, Ahlman H, Tisell LE, Fjälling M, Forssell-Aronsson E, et al. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors. World J Surg 1998;22:679–83

    Article  PubMed  Google Scholar 

  3. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–731

    Article  PubMed  CAS  Google Scholar 

  4. Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, et al. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-Octreotide, 123I-Tyr-3-Octreotide and 111In-DTPA-Phe-1-Octreotide. Eur J Nucl Med 1996;23:1388–99

    Article  PubMed  CAS  Google Scholar 

  5. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–55

    Article  PubMed  Google Scholar 

  6. Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001;12(Suppl 2):41–5

    Article  Google Scholar 

  7. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93

    Article  PubMed  CAS  Google Scholar 

  8. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46

    Article  PubMed  CAS  Google Scholar 

  9. Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumour cell membrane receptors. Cancer Res 1994;54:690–700

    PubMed  CAS  Google Scholar 

  10. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375–8

    PubMed  CAS  Google Scholar 

  11. Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47–57

    Article  PubMed  CAS  Google Scholar 

  12. Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994;733:496–506

    Article  PubMed  CAS  Google Scholar 

  13. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted therapy of small tumors. Acta Oncol 2001;41:602–8

    Article  Google Scholar 

  14. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792–5

    PubMed  CAS  Google Scholar 

  15. Smith-Jones P, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136–48

    Article  PubMed  CAS  Google Scholar 

  16. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82

    Article  PubMed  CAS  Google Scholar 

  17. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumour patients. J Nucl Med 1998;39:1928–36

    PubMed  CAS  Google Scholar 

  18. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704–13

    PubMed  CAS  Google Scholar 

  19. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med Mol Imaging 2001;28:426–34

    Article  CAS  Google Scholar 

  20. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610–6

    PubMed  CAS  Google Scholar 

  21. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, 1998

  22. Mansi L. From the magic bullet to an effective therapy: the peptide experience. Eur J Nucl Med Mol Imaging 2004;31:1393–8

    Article  PubMed  Google Scholar 

  23. Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Investig 1997;27:639–44

    Article  CAS  Google Scholar 

  24. Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912–6

    PubMed  CAS  Google Scholar 

  25. Dorr U, Frank-Raue K, Raue F, Sautter-Bihl ML, Guzman G, Buhr HJ, et al. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun 1993;14:439–45

    Article  PubMed  CAS  Google Scholar 

  26. Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, et al. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl Med Biol 1996;23:503–7

    Article  PubMed  CAS  Google Scholar 

  27. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413–7

    Article  PubMed  CAS  Google Scholar 

  28. Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144–51

    Article  PubMed  CAS  Google Scholar 

  29. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 2001;54:641–9

    Article  CAS  Google Scholar 

  30. Higgins GA, Recant L, Fischman AB. The glucagonoma: surgically curable diabetes. Am J Surg 1979;137:142–8

    Article  PubMed  CAS  Google Scholar 

  31. Prinz RA, Dorsch TR, Lawrence AM. Clinical aspects of glucagon producing islet cell tumors. Am J Gastroenterol 1981;10:58–65

    Google Scholar 

  32. Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 1996;142:193–207

    PubMed  CAS  Google Scholar 

  33. Oeberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 1998;10:58–65

    Article  Google Scholar 

  34. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321–5

    Article  PubMed  CAS  Google Scholar 

  35. Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386–92

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank all technologists involved in the acquisition and processing of the scintigraphic data, and Dr. Peter Angelberger for the preparation and quality control of radiopharmaceuticals. The clinical collaboration of Drs. Robert Dudczak, Amir Kurtaran, Clemens Novotny, Barbara Füger, Maria Leimer, Michael Gabriel, Michaela Greifeneder, Silvia Wogritsch, Ingrid Hurtl and Brigitte Gorz is highlighted. We are grateful to Emilia Halvadjieva, Ernst Havlik and Ruth Freund for their persistent help in our dosimetric calculations.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Margarida Rodrigues.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodrigues, M., Traub-Weidinger, T., Li, S. et al. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 33, 532–540 (2006). https://doi.org/10.1007/s00259-005-0020-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-0020-3

Keywords

Navigation